Modeling of pharmacokinetics of ganciclovir
Pharmacokinetics of ganciclovir by lung transplantation patients
Motol University Hospital
50 participants
Jul 1, 2021
Observational
Conditions
Summary
The aim of this prospective study was to evaluate the pharmacokinetics of ganciclovir in lung transplant recipients and to explore its covariates and propose an individualized ganciclovir dosing regimen.
Eligibility
Inclusion Criteria1
- had undergone lung transplantation and treated with intravenous ganciclovir twice daily for at least 48 hours after transplantation
Exclusion Criteria1
- incomplete date
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Lung transplant patients receiving intravenous ganciclovir (5 mg/kg) twice daily for at least 48 hours after transplantation, blood samples will be collected and ganciclovir levels in the blood will be measured, The duration and frequency of observation in participants, 3-times for the first 24 hours and then in the sixth month post lung-transplant
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12622000645752